

# Evaluation of HBsAb titre in adolescents 15-17 years after Hepatitis B vaccine administration

*Thesis*

*Submitted for partial fulfillment of Master Degree in Pediatrics*

*By*

**Ahmed Fouad Mohammed**

M.B., B.Ch.

Faculty of Medicine - Ain Shams University

*Under Supervision of*

**Dr. Amel El Faramawy**

Professor of Pediatrics

Faculty of Medicine - Ain Shams University

**Dr. Mohammed Eladawy**

Lecturer in pediatrics

Faculty of Medicine - Ain Shams University

**Dr. Amira Hamed**

Associate Assistant professor of Clinical Pathology

Faculty of Medicine - Ain Shams University

~~2012~~2014

## **ACKNOWLEDGMENT**

First of all, I wish to express my endless thanks to **ALLAH** for giving me the help to perform this work.

I would like to express my deepest thanks and highest appreciation to **Prof. Dr. Amel Abd Elmagied El Faramawy** Professor of Pediatrics, Faculty of Medicine Ain Shams University, For her valuable help, precious advice, continuous encouragement and constructive guidance that were the most driving forces for the initiation, progress and completion of this work.

I would like to express my deepest thanks and gratitude to **Dr. Mohammed El Adawy** Lecturer in Pediatrics, Faculty of Medicine Ain Shams University, For his valuable help, precious advice, continuous encouragement and fruitful guidance.

I owe special thanks and gratitude to **Associate. Prof. Dr. Amira Hamed** Associate Professor of Clinical Pathology, Faculty of Medicine, Ain Shams University, For her precious help and fruitful guidance.

I would like to convey my thanks to all the candidates participated in our study for their time and help.

Also, I would like to convey my special thanks to my family for their constant support.

# *LIST OF CONTENTS*

<b>Title</b>	<b>Pages</b>
• List of Content .....	I
• List of Figures .....	II
• List of Tables .....	IV
• List of Abbreviations .....	VII
• Aim of the work .....	x
• Review of Literature .....	1
Introduction .....	1
Epidemiology .....	1
Transmission .....	3
Clinical picture and natural history .....	13
Diagnosis .....	25
Prevention and vaccination .....	35
Treatment .....	58
• Subjects and Methods .....	76
• Results .....	80
• Discussion .....	95
• Summary .....	109
• Conclusion .....	111
• Recommendations .....	112
• References .....	113

## *LIST OF FIGURES*

<b>Fig. No.</b>	<b>Title</b>	<b>Page No.</b>
<b>Figure (1):</b>	Hepatitis B virus Structure .....	1
<b>Figure (2):</b>	Schematic diagram of phases of chronic HBV infection .....	17
<b>Figure (3):</b>	Essential mixed cryoglobulinaemia .....	23
<b>Figure (4):</b>	Papular acrodermatitis .....	24
<b>Figure (5):</b>	Serological profile of acute HBV infection .....	29
<b>Figure (6):</b>	Serological profile of chronic HBV infection .....	29
<b>Figure (7):</b>	Immune response after primary vaccination and memory activation after booster .....	48
<b>Figure (8):</b>	Who and when to treat: algorithm for treatment of children and adolescents with chronic hepatitis B .....	62
<b>Figure (9):</b>	Distribution of the studied group as regards family history of chronic liver diseases .....	82
<b>Figure (10):</b>	Distribution of the studied group as regards blood serum HBsAbs before booster dose .....	84
<b>Figure (11):</b>	Distribution of serum HBsAbs level among the studied candidates before booster dose of HBV vaccine .....	85
<b>Figure (12):</b>	Comparison between negative and positive HBsAbs as regards age and gender .....	86

<b>Figure (13):</b> Comparison between negative and positive HBsAbs as regards residency place .....	87
<b>Figure (14):</b> Comparison between negative and positive HBsAbs as regards social class .....	88
<b>Figure (15):</b> Comparison between negative and positive HBsAbs as regards previous operations .....	89
<b>Figure (16):</b> Effect of booster dose of HBV vaccine on antibody titer among the 56 students .....	93

## *LIST OF TABLES*

Tab. No.	Title	Page No.
<b>Table (1):</b>	Patterns of hepatitis B virus infection.....	2
<b>Table (2):</b>	Phases of HBV infection .....	17
<b>Table (3):</b>	Interpretation of Hepatitis B Virus Test Results .....	28
<b>Table (4):</b>	Hepatitis B Vaccine Routine Infant Schedule .....	41
<b>Table (5):</b>	Recommended doses of currently licensed formulations of hepatitis B vaccine, by age group and vaccine type .....	42
<b>Table (6):</b>	Studies in different populations in regions with different endemicity during the past decade, using anamnestic response to a booster dose .....	50
<b>Table (7):</b>	Data on studies in different populations in regions with different endemicity during the last decade, using measurement of hepatitis B markers as markers for breakthrough infection in vaccinated populations .....	54
<b>Table (8):</b>	Major liver society guidelines for treatment of chronic hepatitis B....	61
<b>Table (9):</b>	Available treatments for chronic hepatitis B in children .....	63
<b>Table (10):</b>	Distribution of the studied group as regards general data .....	80
<b>Table (11):</b>	Distribution of the studied group as regards past history of chronic diseases other than liver diseases .....	81
<b>Table (12):</b>	Distribution of the studied group as family history of chronic liver diseases .....	82
<b>Table (13):</b>	Distribution of the studied group as regards previous operations ...	83

<b>Table (14):</b> Distribution of the studied group as regards blood transfusion .....	83
<b>Table (15):</b> Distribution of the studied group as regards blood serum HBsAbs before booster dose .....	84
<b>Table (16):</b> Distribution of serum HBsAbs level among the studied candidates before booster dose of HBV vaccine .....	85
<b>Table (17):</b> Comparison between negative and positive HBsAbs as regards age and gender .....	86
<b>Table (18):</b> Comparison between negative and positive HBsAbs as regards residency place .....	87
<b>Table (19):</b> Comparison between negative and positive HBsAbs as regards social class .....	88
<b>Table (20):</b> Comparison between negative and positive HBsAbs as regards history of previous operations .....	89
<b>Table (21):</b> Distribution of the studied group as regards HBV obligatory vaccination during 1 <sup>st</sup> year of life and the number of them received a booster dose as a part of the study .....	90
<b>Table (22):</b> Distribution of the studied group who received booster dose of HBV vaccines as regards general data .....	91
<b>Table (23):</b> Effect of booster dose of HBV vaccine on antibody titer among the 56 candidates .....	92
<b>Table (24):</b> Distribution of serum HBsAbs among 56 candidates before and after booster dose of HBV vaccine as regards Gender .....	94

**Table (25):** Distribution of serum HBsAbs among 56 candidates before and after booster dose of HBV vaccine as regards Residence ..... 94

**Table (26):** Non Egyptian studies for evaluation of immunogenicity and efficacy of HBV vaccination after 1<sup>st</sup> obligatory vaccines ..... 98



## *LIST OF ABBREVIATIONS*

<b>Abbrev.</b>	<b>Meaning</b>
HBV	Hepatitis B virus
DNA	Deoxynucleic acid
ccc DNA	covalently closed circular DNA
RNA	Ribonucleic Acid
HBsAg	Hepatitis B surface Antigen
qHBsAg	quantification of Hepatitis B surface Antigen
HBcAg	Hepatitis B core Antigen
HBeAg	Hepatitis B e Antigen
HBsAbs	Hepatitis B surface Antibodies
HBcAbs (anti-HBc)	Hepatitis B core Antibodies
HBeAbs	Hepatitis B e Antibodies
HIV	Human Immunodeficiency Virus
MTCT	Mother to Child Transmission
HBIG	Hepatitis B Immunoglobulin
NAT	Nucleic Acid Testing
CHB	Chronic Hepatitis B
ALT	Alanine Aminotransferase

AST	:	Aspartate Aminotransferase
GGT	:	Gamma Glutamyl Transpeptidase
HCC	:	Hepatocellular Carcinoma
HCV	:	Hepatitis C Virus
PAN	:	Polyarteritis nodosa
RIA	:	Radioimmunoassay
EIA	:	Enzyme Immunoassay
PCR	:	Polimerase Chain Reaction
WHO	:	World Health Organization
CDC	:	Centers for Disease Control and Prevention
EASL	:	European Association for the Study of the Liver
AASLD	:	American Association for the Study of Liver ds
APASL	:	Asia-Pacific Association for the Study of the Liver
USPSTF	:	US Preventive Service Task Force
DPT- OPV	:	Diphtheria, Tetanus, Pertussis and Oral Polio
HLA	:	Human Leukocyte Antigen
PEP	:	Post Exposure Prophylaxis
MS	:	Multiple Sclerosis
ULN	:	Upper Limit of Normal

FDA	:	Food and Drug Administration
IFN	:	Interferon alfa
IFN	:	Interferon Gamma
VR	:	Virological Responses
LAM	:	Lamivudine
LdT	:	Telbivudine
ETV	:	Entecavir
NA	:	Nucleoside/tide Analogue
ELI spot	:	Enzyme-Linked Immunospot assay
HCWs	:	Health care workers
SOC	:	Standard Of Care



# ~~Evaluation of HBsAb titre in adolescents 15-17 years after Hepatitis B vaccine administration~~

---

*Thesis*

*Submitted for partial fulfillment of Master Degree in Pediatrics*

*By*

**Ahmed Fouad Mohammed**

M.B., B.Ch.

Faculty of Medicine – Ain Shams University

*Under Supervision of*

**Dr. Amel El Faramawy**

Assistant professor of Pediatrics

Faculty of Medicine – Ain Shams University

**Dr. Mohammed Eladawy**

Lecturer in pediatrics

Faculty of Medicine – Ain Shams University

**Dr. Amira Hamed**

Assistant professor of Clinical Pathology

Faculty of Medicine – Ain Shams University

2012

## Introduction

Egypt is considered as a region of intermediate prevalence for HBV infection with reported figure of 4.5%. Infection with HBV in infancy or early childhood may lead to a high rate of persistent infection (25–90%), while the rates are lower if infection occurs during adulthood (5–10%) (WHO, 2007).

In most endemic areas, infection occurs mainly during early childhood and mother-to-infant transmission accounts for approximately 50% of the chronic infection cases (Chang, 2007).

Neonatal HBV vaccination is the most effective measure for prevention of HBV infection in countries with intermediate to high levels of HBV endemicity (Puvacic *et al.* 2004). A compulsory vaccination programme against hepatitis B infection among infants was started in Egypt in 1992 using a yeast recombinant DNA vaccine (10 µg) and with a schedule of 2, 4 and 6 months of age (Mansour *et al.*, 1993).

Seroprotection is assured when hepatitis B surface antibody (anti-HBs) level is > 10 IU/L (Floreani *et al.*, 2004). The duration of protection in low risk infants whose mothers are negative for HBsAg and who receive hepatitis B vaccine from birth is unknown. In these populations the risk of HBV infection increases during adolescent and early adulthood (CDC, 2007).

Serologic studies have shown that the titer of antibodies against hepatitis B surface antigen drops within the first few years after vaccination and that one-third to one half of children vaccinated as infants will have titers below 10 IU/L by 10–15 years of age (Dentinger *et al.* , 2005).

Previous studies were done in Egypt ; In Al - Azhar university the long-term immunity to hepatitis B was assessed among vaccinated (245) children aged 6–11 years, (39.3%) of them had protective level of anti-HBs (>10 IU/L). ( Afifi et al., 2009). In Menoufia University, Sero

protection against HBsAg was studied in 200 vaccinated children. Children were divided into two groups. Group A, (100 child around 6 years) of whom 19 (19%) had HBsAb titre < 10 mIU/ mL & 81 (81%) had HBsAb titre 10mIU/ mL. While in Group B, (100 child around 11 years), 52 child (52%) had HBsAb titre < 10 mIU/ mL & 48 (48%) had HBsAb titre 10mIU/mL. (El-Sayed B, et al.,2009).

Also in Alexandria university, a seroepidemiologic study was conducted to examine the impact of HB vaccination on the carrier state among a vaccinated group of children (1000) compared to a non vaccinated group (500) aged 6ys. The efficacy of HB vaccine in preventing the carriage of HbsAg, 5 ys after full course vaccination was estimated to be around (67%). (Reda A.A et al.,2003)

## **Aim of the study**

~~The aim of this study is to evaluate the HB surface antibody titer in adolescents aged 15-17 years who had received a full vaccination course during infancy.~~

## **Methods & population**

### **Population:**

- ~~• Hundred and fifty healthy first-year students in the Faculty of Medicine-Ain-Shams University.~~

### **Inclusion criteria:**

- ~~• Healthy adolescent who is 15-17 year old and received full hepatitis B virus vaccination course according to Egyptian Expanded Immunizing Protocol (EEIP) during infancy.~~

### **Exclusion criteria:**

- ~~• Adolescent who did not receive a full vaccination course during infancy.~~
- ~~• Adolescent that received a full vaccination course after infancy.~~
- ~~• Adolescent that received a booster dose after the initial vaccination course during infancy.~~
- ~~• Adolescent with hematological, renal or chronic liver disease.~~